Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223

CompletedOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

January 17, 2015

Primary Completion Date

February 1, 2015

Study Completion Date

March 1, 2018

Conditions
Prostate Cancer MetastaticBone Metastases
Interventions
DRUG

Radium-223 dichloride

Registry of patients who receive Radium-223.

Trial Locations (20)

3818 ES

Meander Medical Center, Amersfoort

Unknown

Jeroen Bosch Hospital, 's-Hertogenbosch

Noordwest Ziekenhuisgroep, Alkmaar

Zorggroep Twente, Almelo

Rijnstate, Arnhem

Amphia Ziekenhuis, Breda

Reinier de Graaf Hospital, Delft

Deventer Ziekenhuis, Deventer

Catharina Ziekenhuis, Eindhoven

Groene Hart Ziekenhuis, Gouda

Martini Ziekenhuis, Groningen

Spaarne Gasthuis, Hoofddorp

Antonius Ziekenhuis, Nieuwegein

Haga Ziekenhuis, The Hague

MC Haaglanden, The Hague

Universitair Medisch Centrum Utrecht, Utrecht

Isala Klinieken, Zwolle

1066CX

The Netherlands Cancer Intitute, Amsterdam

6401 CX

Atrium Medisch Centrum Parkstad, Heerlen

3045 PM

Franciscus Gasthuis-Vlietland, Rotterdam

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT03223597 - Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223 | Biotech Hunter | Biotech Hunter